{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:30:13Z","timestamp":1792884613192,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41375-025-02633-3","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T02:44:21Z","timestamp":1747104261000},"page":"1595-1606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"39","author":[{"given":"Ruth W.","family":"Wang\u2019ondu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ashcraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5302-9147","authenticated-orcid":false,"given":"Ti-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-4043","authenticated-orcid":false,"given":"Kathryn G.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-7800","authenticated-orcid":false,"given":"Samuel W.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-5322","authenticated-orcid":false,"given":"William","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-9591","authenticated-orcid":false,"given":"Mary V.","family":"Relling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-558X","authenticated-orcid":false,"given":"Kristine R.","family":"Crews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-9659","authenticated-orcid":false,"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-5649","authenticated-orcid":false,"given":"Wenjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9167-2114","authenticated-orcid":false,"given":"Stanley","family":"Pounds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-5864","authenticated-orcid":false,"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-3478","authenticated-orcid":false,"given":"Meenakshi","family":"Devidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8409-0589","authenticated-orcid":false,"given":"Leonard","family":"Mattano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-2168","authenticated-orcid":false,"given":"Reuven J.","family":"Schore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6626-2773","authenticated-orcid":false,"given":"Michael J.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-4700","authenticated-orcid":false,"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Jeha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0303-5658","authenticated-orcid":false,"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-7342","authenticated-orcid":false,"given":"Hiroto","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-1850","authenticated-orcid":false,"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2633_CR1","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol. 2012;30:1663\u20139.","journal-title":"J Clin Oncol"},{"key":"2633_CR2","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","volume":"360","author":"CH Pui","year":"2009","unstructured":"Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Eng J Med. 2009;360:2730\u201341.","journal-title":"N Eng J Med"},{"key":"2633_CR3","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","volume":"34","author":"EC Larsen","year":"2016","unstructured":"Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: A report from children\u2019s oncology group study AALL0232. J Clin Oncol. 2016;34:2380\u20138.","journal-title":"J Clin Oncol"},{"key":"2633_CR4","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41375-021-01460-6","volume":"36","author":"MJ Burke","year":"2022","unstructured":"Burke MJ, Devidas M, Chen Z, Salzer WL, Raetz EA, Rabin KR, et al. Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children\u2019s Oncology Group Study AALL0232. Leukemia. 2022;36:648\u201355.","journal-title":"Leukemia"},{"key":"2633_CR5","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1200\/JCO.23.01286","volume":"41","author":"R Pieters","year":"2023","unstructured":"Pieters R, Mullighan CG, Hunger SP. Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL. J Clin Oncol. 2023;41:5579\u201391.","journal-title":"J Clin Oncol"},{"key":"2633_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470\u201380.","journal-title":"N Engl J Med"},{"key":"2633_CR7","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla M, Dagdan E, Zaliova M, M\u00f6ricke A, Palmi C, Cazzaniga G, et al. IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36:1240\u20139.","journal-title":"J Clin Oncol"},{"key":"2633_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/hon.2973","volume":"40","author":"M Braun","year":"2022","unstructured":"Braun M, Pastorczak A, Sedek L, Taha J, Madzio J, Jatczak-Pawlik I, et al. Prognostic significance of IKZF1 deletions and IKZF1plus profile in children with B-cell precursor acute lymphoblastic leukemia treated according to the ALL-IC BFM 2009 protocol. Hematological Oncol. 2022;40:430\u201341.","journal-title":"Hematological Oncol"},{"key":"2633_CR9","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/leu.2015.134","volume":"29","author":"E Clappier","year":"2015","unstructured":"Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P, et al. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children\u2019s Leukemia Group study 58951. Leukemia. 2015;29:2154\u201361.","journal-title":"Leukemia"},{"key":"2633_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30313","volume":"70","author":"M Kicinski","year":"2023","unstructured":"Kicinski M, Arfeuille C, Grardel N, Bakkus M, Caye-Eude A, Plat G, et al. The prognostic value of IKZF1(plus) in B-cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial. Pediatr Blood Cancer. 2023;70:e30313.","journal-title":"Pediatr Blood Cancer"},{"key":"2633_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","volume":"123","author":"A Van Der Veer","year":"2014","unstructured":"Van Der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood. 2014;123:1691\u20138.","journal-title":"Blood"},{"key":"2633_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110\u20134.","journal-title":"Nature"},{"key":"2633_CR13","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2011.40.3907","volume":"30","author":"AV Moorman","year":"2012","unstructured":"Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, et al. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol. 2012;30:3100\u20138.","journal-title":"J Clin Oncol"},{"key":"2633_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/leu.2013.277","volume":"28","author":"E Clappier","year":"2014","unstructured":"Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia. 2014;28:70\u20137.","journal-title":"Leukemia"},{"key":"2633_CR15","doi-asserted-by":"publisher","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","volume":"115","author":"JF Li","year":"2018","unstructured":"Li JF, Dai YT, Lilljebj\u00f6rn H, Shen SH, Cui BW, Bai L, et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci USA. 2018;115:E11711\u2013E20.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2633_CR16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758\u201364.","journal-title":"Nature"},{"key":"2633_CR17","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo M-C, et al. Dasatinib\u2013Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"2633_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41375-021-01496-8","volume":"36","author":"Y Sasaki","year":"2022","unstructured":"Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, et al. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022;36:1253\u201360.","journal-title":"Leukemia"},{"key":"2633_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/ng.3691","volume":"48","author":"J Zhang","year":"2016","unstructured":"Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016;48:1481\u20139.","journal-title":"Nat Genet"},{"key":"2633_CR20","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1038\/leu.2012.84","volume":"26","author":"TD Buitenkamp","year":"2012","unstructured":"Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JPP, Beverloo HB, et al. Outcome in children with Down\u2019s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia. 2012;26:2204\u201311.","journal-title":"Leukemia"},{"key":"2633_CR21","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3109\/10428194.2016.1144881","volume":"57","author":"R DeBoer","year":"2016","unstructured":"DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, et al. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016;57:2298\u2013306.","journal-title":"Leuk Lymphoma"},{"key":"2633_CR22","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/leu.2017.154","volume":"31","author":"L Hinze","year":"2017","unstructured":"Hinze L, M\u00f6ricke A, Zimmermann M, Junk S, Cario G, Dagdan E, et al. Prognostic impact of IKZF1 deletions in association with vincristine\u2013dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95. Leukemia. 2017;31:1840\u20132.","journal-title":"Leukemia"},{"key":"2633_CR23","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1001\/jamaoncol.2021.2723","volume":"7","author":"DS Mangum","year":"2021","unstructured":"Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, et al. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol. 2021;7:1521\u20138.","journal-title":"JAMA Oncol"},{"key":"2633_CR24","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","volume":"27","author":"G Martinelli","year":"2009","unstructured":"Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report. J Clin Oncol. 2009;27:5202\u20137.","journal-title":"J Clin Oncol"},{"key":"2633_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.13514","volume":"170","author":"L Olsson","year":"2015","unstructured":"Olsson L, Ivanov \u00d6fverholm I, Nor\u00e9n-Nystr\u00f6m U, Zachariadis V, Nordlund J, Sj\u00f6gren H, et al. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. Br J Haematol. 2015;170:847\u201358.","journal-title":"Br J Haematol"},{"key":"2633_CR26","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1200\/JCO.22.02705","volume":"41","author":"R Pieters","year":"2023","unstructured":"Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, et al. Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups. J Clin Oncol. 2023;41:4130\u201342.","journal-title":"J Clin Oncol"},{"key":"2633_CR27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3324\/haematol.2011.056135","volume":"98","author":"D Petra","year":"2013","unstructured":"Petra D, Barbara M, Martin Z, Anja M, Andr\u00e9 S, Jean-Pierre B, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013;98:428\u201332.","journal-title":"Haematologica"},{"key":"2633_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3324\/haematol.2011.056135","volume":"98","author":"P Dorge","year":"2013","unstructured":"Dorge P, Meissner B, Zimmermann M, Moricke A, Schrauder A, Bouquin JP, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013;98:428\u201332.","journal-title":"Haematologica"},{"key":"2633_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","volume":"2","author":"S Jeha","year":"2021","unstructured":"Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, et al. Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease\u2013Directed Therapy. Blood Cancer Discov. 2021;2:326.","journal-title":"Blood Cancer Discov"},{"key":"2633_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389.","journal-title":"Nat Genet"},{"key":"2633_CR31","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1200\/JCO.23.02238","volume":"42","author":"TC Chang","year":"2024","unstructured":"Chang TC, Chen W, Qu C, Cheng Z, Hedges D, Elsayed A, et al. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J Clin Oncol. 2024;42:3491\u2013503.","journal-title":"J Clin Oncol"},{"key":"2633_CR32","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.01692","volume":"37","author":"S Jeha","year":"2019","unstructured":"Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, et al. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019;37:3377\u201391.","journal-title":"J Clin Oncol"},{"key":"2633_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pcl.2014.09.009","volume":"62","author":"KW Maloney","year":"2015","unstructured":"Maloney KW, Taub JW, Ravindranath Y, Roberts I, Vyas P. Down syndrome preleukemia and leukemia. Pediatr Clin North Am. 2015;62:121\u201337.","journal-title":"Pediatr Clin North Am"},{"key":"2633_CR34","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1200\/JCO.20.02370","volume":"39","author":"LA Mattano Jr","year":"2021","unstructured":"Mattano LA Jr, Devidas M, Maloney KW, Wang C, Friedmann AM, Buckley P, et al. Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children\u2019s Oncology Group Trial AALL0331. J Clin Oncol. 2021;39:1540\u201352.","journal-title":"J Clin Oncol"},{"key":"2633_CR35","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41375-023-01870-8","volume":"37","author":"RJ Schore","year":"2023","unstructured":"Schore RJ, Angiolillo AL, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. Leukemia. 2023;37:1375\u20138.","journal-title":"Leukemia"},{"key":"2633_CR36","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.20.00494","volume":"39","author":"AL Angiolillo","year":"2021","unstructured":"Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children\u2019s Oncology Group AALL0932. J Clin Oncol. 2021;39:1437\u201347.","journal-title":"J Clin Oncol"},{"key":"2633_CR37","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.19.02892","volume":"38","author":"WL Salzer","year":"2020","unstructured":"Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, et al. Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children\u2019s Oncology Group Study AALL1131. J Clin Oncol. 2020;38:2628\u201338.","journal-title":"J Clin Oncol"},{"key":"2633_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","volume":"51","author":"Z Gu","year":"2019","unstructured":"Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genet. 2019;51:296\u2013307.","journal-title":"Nature Genet"},{"key":"2633_CR39","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1182\/blood.2022015444","volume":"139","author":"S Kimura","year":"2022","unstructured":"Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, et al. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022;139:3519\u201331.","journal-title":"Blood"},{"key":"2633_CR40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/blood.2022019094","volume":"142","author":"Q Gao","year":"2023","unstructured":"Gao Q, Ryan SL, Iacobucci I, Ghate PS, Cranston RE, Schwab C, et al. The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Blood. 2023;142:711\u201323.","journal-title":"Blood"},{"key":"2633_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ccell.2015.07.016","volume":"28","author":"ML Churchman","year":"2015","unstructured":"Churchman ML, Low J, Qu C, Paietta EM, Kasper LH, Chang Y, et al. Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell. 2015;28:343\u201356.","journal-title":"Cancer Cell"},{"key":"2633_CR42","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ccell.2018.03.021","volume":"33","author":"ML Churchman","year":"2018","unstructured":"Churchman ML, Qian M, te Kronnie G, Zhang R, Yang W, Zhang H, et al. Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell. 2018;33:937\u201348.e8.","journal-title":"Cancer Cell"},{"key":"2633_CR43","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1182\/blood-2015-09-671131","volume":"126","author":"CG Mullighan","year":"2015","unstructured":"Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, et al. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood. 2015;126:2896\u20139.","journal-title":"Blood"},{"key":"2633_CR44","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1200\/JCO.18.00822","volume":"37","author":"CH Pui","year":"2019","unstructured":"Pui CH, Rebora P, Schrappe M, Attarbaschi A, Baruchel A, Basso G, et al. Outcome of children with hypodiploid acute lymphoblastic leukemia: A retrospective multinational study. J Clin Oncol. 2019;37:770\u20139.","journal-title":"J Clin Oncol"},{"key":"2633_CR45","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3324\/haematol.2018.204487","volume":"104","author":"Z Marketa","year":"2019","unstructured":"Marketa Z, Eliska P, Lenka H, Alena M, Lucie W, Karel F, et al. ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity. Haematologica. 2019;104:1407\u201316.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02633-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T03:02:47Z","timestamp":1751252567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02633-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2633"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02633-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5292018\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CGM has received consulting fees from Illumina, speaking fees\/honoraria from Amgen, and research funding from Pfizer. HI has received consulting fees from Jazz Pharmaceuticals and Servia, and research funding from Servier, Amgen, and Incyte.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}